Pre-exposure Prophylaxis Against Human Immunodeficiency Virus

ÇINAR G., BİRENGEL M. S.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, cilt.23, sa.1, ss.1-7, 2018 (ESCI) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 23 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5578/flora.66513
  • Dergi Adı: FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-7
  • Anahtar Kelimeler: Human immunodeficiency virus, Prevention, Pre-exposure prophylaxis, TENOFOVIR DISOPROXIL FUMARATE, HIV-INFECTION, COST-EFFECTIVENESS, UNITED-STATES, ANTIRETROVIRAL PROPHYLAXIS, DOUBLE-BLIND, MEN, PREVENTION, SEX, WOMEN
  • Ankara Üniversitesi Adresli: Evet

Özet

According to the Center for Disease Control and Prevention (CDC), there were 2.1 million new human immunodeficiency virus (HIV) cases reported worldwide in 2015, which shows that siginificant work needs to be done to prevent the transmission of HIV. Research to date has focused mainly on high-risk men who have sex with men, but many women around the world are also at a high risk for HIV transmissions. In studies conducted, the incidence of HIV infection in high-risk individuals decreases over 90% when high-risk individuals use pre-exposure prophylaxis (PreP) HIV, tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) safely. Current data and studies on pre-exposure prophylaxis were discussed in this review.